Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Lancet Infect Dis. 2015 Nov 2;16(2):199–208. doi: 10.1016/S1473-3099(15)00345-X

Table 1.

Baseline characteristics of study sample by treatment allocation

Covariate Placebo (N=184) Praziquantel (N=186)
Age ψ 25.9 (6.26) 26.2 (6.60)
SES quartile
  1st quartile 21 (11%) 26 (14%)
  2nd quartile 67 (36%) 73 (39%)
  3rd quartile 46 (25%) 46 (25%)
  4th quartile 50 (27%) 41 (22%)
Current Smoking Status
  No 183 (99%) 185 (99%)
  Yes 1 (1%) 1 (1%)
Current Alcohol Consumption
  No 48 (26%) 39 (21%)
  Yes 136 (74%) 147 (79%)
Height (cm)ψ 147.1 (5.8) 147.8 (5.2)
Weight (Kg)ψ 47.3 (7.5) 47.8 (7.0)
S. japonicum epg at screening* 10.00, 26.67 10.00, 26.67
S. japonicum epg at screeningψ 40.4 (95.3) 32.7 (58.3)
A. lumbricoides epg at
screening*
475.0, 7923 803.3, 8460
Prevalence of A. lubricoides
infection at screening
112/184 (61%) 115/186 (62%)
Hookworm epg at screening * 0.00, 23.33 0.00, 23.33
Prevalence of hookworm
infection at screening
61/184 (33%) 72/186 (39%)
T. trichiura epg at screening * 83.33, 290.0 101.7, 290.0
Prevalence of T. trichiura
infection at screening
146/184 (79%) 153/186 (82%)
History of any obstetrical
complication
28(15.22%) 31(16.67%)
Number of prior pregnancies
  1–5 151 (82%) 141 (76%)
  6–10 32 (17%) 45 (24%)
  11+ 1 (1%) 0 (0%)
ψ

Mean (SD).

*

Parasitologic results prior to treatment as determined by Kato-Katz and reported as eggs per gram of stool. Median, interquartile range.